Are you also significantly less optimistic about AGN's dual-acting (VEGF/PDGF) DARPin in preclinical development? According to yesterday's CC, the plans and timeline for this drug haven't changed at all, but this assertion might include a modicum of spin.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”